心肌病,肥大性

摘要： Objective: The feature tracking technique of cardiac magnetic resonance (CMR-FT) was used to analyze the cardiac function and myocardial segmental strain in patients with hypertrophic cardiomyopathy (HCM), and to explore the feasibility of CMR-FT in the detection of early deformation abnormalities in patients with hypertrophic cardiomyopathy. Materials and Methods: 17 hypertrophic cardiomyopathy patients and 14 healthy subjects as control cases were enrolled in our study. CMR was performed on 3.0 T scanner with the sequence of cine steady-state free precession. Cardiac functional segmental strain (38 segments of HCM and 38 segments of healthy subjects) was measured using CVI software. Results:Left ventricular function parameters (left ventricular end-diastolic volume, left ventricular end-systolic volume and left ventricular ejection fraction) had no difference between HCM patients and healthy subjects (all P>0.05). Segmental strain were significantly lower in patients with HCM compared to healthy subjects (all P0.05),肥厚的心肌节段的圆周应变、长轴应变及峰值收缩期圆周应变、峰值收缩期长轴应变均低于正常的心肌节段[(-5.26±2.70)%vs(-11.68±2.06)%,(-7.92±5.07)%vs(-13.93±3.89)%,(-10.44±5.46)%vs(-18.43±2.99)%,(-12.29±8.17)%vs(-20.26±2.93)%,P均<0.05].结论 对于心功能正常的肥厚性心肌病患者,CMR-FT技术能够早期检测出肥厚患者肥厚心肌节段应变的变化,提示心肌应变量的改变能够比左心室功能参数更早地发现心肌收缩功能异常.

摘要： Objective To assess left atrial (LA) function by two dimensional speckle tracking echocardiography (2DSTE) in patients with hypertrophic obstructive cardiomyopathy (HOCM) before and one year after percutaneous transluminal septal myocardial ablation (PTSMA).Methods The study included 31 patients with HOCM who underwent PTSMA performed between November 2012 and December 2014 in Sir Run Run Shaw Hospital.Mean age was 51 ± 13 years,and 13 patients were men,18 patients were women.New York Heart Association class was 2.6± 0.7 at baseline.If the target region was correctly marked by the injection of the echo contrast agent,ethanol was slowly (0.5 ml/min) injected to a maximum of 3 ml.Ten minutes after the injection of ethanol,the balloon was deflated.A successful procedure was defined as a ≥ 50％ reduction in the LV outflow tract peak systolic gradient compared to baseline level.Each patient with HOCM had a complete two-dimensional transthoracic echocardiography assessment before and one year after the PTSMA.The measurements included basal septal thickness,left ventricular outflow tract (LVOT) gradient,mitral regurgitation (MR) grade,left atrial dimensions,left ventricular (LV) ejection fraction and tissue Doppler parameters of lateral mitral annular e'and septal mitral annular e'.The LA wall was tracked on a frame-by-frame basis using 2D-STE,and LA volume waveforms were generated.The maximum LA volume (LAVmax),minimal LA volume (LAVmin),and the LA volume before atrial contraction (LAVpre-a) were measured.The LA reservoir function was calculated as left atrial expansion index (LAEI) and left atrial diastolic emptying index (LADEI).The LA conduit function was calculated as the passive emptying percentage of total emptying (PE) and the passive emptying index (PEI).The LA booster function was calculated as the active emptying percentage of total emptying (AE) and the active emptying index (AEI).The comparisons between patient New York Heart Association class,echocardiography and LA function parameter before and after PTSMA were conducted by paired t test.Results Compared with pre-operative values,LVOTG,MR grade,LA end-diastolic size,E/lateral e'ratio,septal mitral annular e'decreased in patients one year after the PTSMA [(35±26) mmHg vs (74135) mmHg,0.9310.35 vs 2.27±0.73,(40±6) mm vs (45±6) mm,12.6±3.8 vs 14.6±4.6,(4.3± 1.1) cm/s vs (5.0± 1.3) cm/s],whereas New York Heart Association class,Lateral mitral annular e',E/septal e'ratio [1.4±0.5 vs 2.6±0.7,(6.9±2.3) cm/s vs (5.8± 1.7) cm/s,20.2±7.1 vs 17.0±5.2] increased (t=6.55,4.78,2.60,2.84,2.59,-3.32,-2.67,-2.93,all P ＜ 0.05).Compared with pre-operative values,LAVImax,LAVImin,LAVIpre-a,AE,AEI(％) decreased in patients one year after the PTSMA [(32.7±7.1) ml/m2 vs (38.9±9.3) ml/m2,(16.3±4.4) ml/m2 vs (20.7±5.5) ml/m2,(23.1±5.7) ml/m2 vs (30.5±7.0) ml/m2,(41.5±8.7)％ vs (53.8± 10.4)％,(29.4±3.9)％ vs (32.1±4.6)％],(t=3.65,3.11,3.38,3.92,2.17,all P ＜ 0.05);whereas the LAEI(％),LADEI(％),PE(％),PEI(％) [(100.1 ± 19.3)％ vs (87.9± 14.7)％,(50.2±9.8)％ vs (46.7±9.1) ％,(58.5± 11.8) ％ vs (46.1 ±9.1) ％,(26.9±5.2)％ vs (21.6±4.8)％] increased (t=-2.82,-2.33,-3.89,-2.74,all P ＜ 0.05).Conclusions The study showed the improvement in LA reservoir and conduit function,while the reduction in LA booster pump function in patients one year after PTSMA.%目的 应用二维斑点追踪技术对肥厚型梗阻性心肌病(HOCM)患者经皮经冠状动脉室间隔化学消融术(PTSMA)术前及术后1年左心房功能的评估.方法 选取2012年11月至2014年12月在浙江大学医学院附属邵逸夫医院行PTSMA手术HOCM患者31例,其中,男性13例,女性18例,年龄22～71岁,平均年龄(51±13)岁.心功能NYHA分级为(2.6±0.7)级.如果靶区域超声造影剂显示正常,通过球囊中心腔向导管腔内缓慢推注无水乙醇增大剂量3.0 ml,保持球囊充盈10 min.以LVOTG下降≥50％作为手术成功的标准.于室间隔化学消融术前及术后1年接受超声心动图检查.测量包括左心室流出道压差(LVOTG),二尖瓣关闭不全(MR)的程度,左心房前后径,左心室射血分数(LVEF)和组织多普勒(TDI)测定二尖瓣环舒张早期峰值速度e'(取室间隔和侧壁).采用二维斑点追踪技术自动追踪左心房壁,并获取左心房容积曲线,获得左心房最大容积(LAVmax)、左心房最小容积(LAVmin)及左心房收缩前容积(LAVpre-a).计算出左心房储备功能包括左心房充盈扩张分数(LAEI)及左心房舒张期排空分数(LADEI)、左心房管道功能包括左心房被动排空比(PE)及被动排空指数(PEI)、左心房泵功能包括左心房主动排空比(AE)及主动排空指数(AEI).PTSMA术前及术后患者心功能NYHA分级、超声心动图测量结果、左心房容积参数之间的比较采用配对f检验.结果 PTSMA术后1年与术前比较,LVOTG、MR的程度、左心房前后径、E/侧壁e'比值、二尖瓣环室间隔e'均下降,差异均有统计学意义[(35±26) mmHg vs (74±35) mmHg(1 mmHg=0.133 kPa)、0.93±0.35 vs 2.27±0.73、(40±6) mm vs (45±6) mm、12.6±3.8 vs14.6±4.6、(4.3±1.1) cm/s vs(5.0±1.3) cm/s,t=6.55、4.78、2.60、2.84、2.59,P均＜0.05];心功能NYHA分级、二尖瓣环侧壁e'、E/室间隔e'比值增加,差异均有统计学意义[1.4±0.5 vs 2.6±0.7、(6.9±2.3) cm/s vs (5.8±1.7) cm/s、20.2±7.1 vs 17.0±5.2,t=-3.32、-2.67、-2.93,P均＜0.05].消融术后1年与术前比较,LAVImax,LAVImin、LAVIpre-a、AE、AEI(％)下降[(32.7±7.1) ml/m2vs (38.9±9.3) ml/m2、(16.3±4.4) ml/m2 VS (20.7±5.5) ml/m2、(23.1±5.7) ml/m2vs (30.5±7.0) ml/m2、(41.5±8.7)％vs (53.8±10.4)％、(29.4±3.9)％vs (32.1±4.6)％],差异均有统计学意义(t=3.65、3.11、3.38、3.92、2.17,P均＜0.05);LAEI(％)、LADEI(％)、PE(％)、PEI(％) 增加[(100.1±19.3)％vs(87.9±14.7)％、(50.2±9.8)％ vs (46.7±9.1)％、(58.5±11.8)％ vs (46.1±9.1)％、(26.9±5.2)％vs (21.6±4.8)％],差异均有统计学意义(t=-2.82、-2.33、-3.89、-2.74,P均＜0.05).结论 HOCM患者室间隔消融术后1年左心房的储备及管道功能得到改善,而左心房泵功能及主动收缩耗能下降.

摘要： 肥厚型心肌病(hypertrophic cardiomyopathy,HCM)是常见的常染色体显性遗传性心脏病,其病因复杂,临床表现多样,临床特征是左心室非对称性的肥厚,且这种肥厚不能用其他心脏疾病或全身疾病来解释.随着HCM诊治手段的不断发展、更新,对HCM认识也越来越深入,其治疗方法亦在不断发展.目前治疗上仍主要以防治并发症(尤其是心源性猝死)、减轻患者症状、延缓疾病进展为主,包括一般治疗、药物治疗和非药物治疗.通过阅读相关文献,就HCM的治疗方法作一综述.

摘要： [目的]探讨炎症因子的表达与心肌肥厚性改变的相关性.[方法]将40只体重在180~200 g的雄性SD大鼠随机分为两组,实验组(25只)制作压力负荷性心肌肥厚大鼠模型,对照组肾动脉不作处理.手术56 d后用ELISA方法测量比较两组心肌组织肿瘤坏死因子(TNF-α)与白细胞介素-6(IL-6)的含量,并比较两组左室心肌重量.[结果]两组大鼠TNF-α和IL-6水平比较差异有显著性(P<0.05);且实验组大鼠的左室壁明显肥厚,重量明显增加(P<0.05).[结论]实验组大鼠心肌组织TNF-α、IL-6表达水平与左室心肌重量成正相关,并参与了左室肥厚的形成过程.%[Objective]To explore the correlation between the expression of inflammatory factors and the change about myocardial hypertrophy. [Methods]Forty healthy male Sprague-Dawley rats weighed 180~200 g were randomly divided into two groups. Experiment group ( n =25) was used for establishing rat model of pressure-overload hypertrophy, while control group did not receive the operation of renal artery. Inflammatory factors such as tumor necrosis factor-alpha(TNF-α) and interleukin-6(IL-6) in myocardium were measured and compared between two groups by using ELISA 56 days after the operation. [Results]There was significant difference in TNF-α and IL-6 between two groups( P <0. 05). In experiment group, left ventricular wall of rats had obvious hypertrophy and the weight significantly increased( P <0. 05). [Conclusion]The expression of TNF-a and IL-6 in myocardium is positively correlated with left ventricular mass of rats in experiment group, which participates in the formation of left ventricular hypertrophy.

摘要： 目的:观察短期应用阿托伐他汀对扩张型心肌病(DCM)心力衰竭患者心功能及C反应蛋白(CRP)、血浆脑钠肽(BNP)的影响.方法:选择DCM心力衰竭患者40例,随机分为治疗组20例,对照组20例.对照组常规应用纠正心力衰竭药物治疗,治疗组在常规治疗基础上加用阿托伐他汀40 mg,每晚1次,疗程12周.2组入选后次日及治疗12周后测定左心室射血分数(LVEF)、血浆CRP、BNP水平.结果:2组LVEF较治疗前显著提高(P<0.01),治疗组与对照组差异有统计学意义(P<0.01).2组CRP和BNP水平均较治疗前显著降低(P<0.01),治疗组与对照组差异均有统计学意义(P<0.01).结论:短期应用阿托伐他汀可降低DCM心力衰竭患者CRP水平,改善心功能,有效抑制BNP水平.其改善心功能作用机制可能与他汀类调脂以外的抗炎作用有部分关系,短期应用他汀类治疗DCM心力衰竭可能是有益的.%Objective:To observe the effect of atorvastatin on cardiac function, C-reaction protein(CRP) and serum level of brain natriuretic peptide(BNP) in patients of heart failure(HF) with dilated cardiomyopathy(DCM). Methods :Forty patients with DCM and HF were randomly divided into treatment group and control group. The control group was given conventional drug therapy. The treatment group was given atorvastatin(40 mg/d, 12 weeks) in addition to routine treatment. The left ventricular ejection fraction (LVEF), CRP and BNP were measured before and after treatment. Results: After 12 weeks, the LVEF was dramatically higher in all patients ( P ＜ 0.01 ) ,and the LVEF in treatment group was significantly higher than that in the conventional therapy group( P ＜ 0.01 ). The serum level of CRP and BNP was dramatically lower in all patients( P ＜ 0.01 ). Also, the serum level of CRP and BNP was significantly lower in the treatment group when compared with that of control group(P ＜ 0.01 ). Conclusions :Short-term use of atorvastatin can decrease serum levels of CRP and BNP in Patients of HF with DCM, and improve cardiac function. The mechanism of action may be related to anti-inflammatory effeet. It may be useful to short-term use of statin therapy.

摘要： 目的 探讨门控心肌灌注显像评价肥厚型心肌病患者心肌缺血情况的临床应用价值.方法 选取核素心肌灌注显像均为阳性的69例临床确诊的肥厚型心肌病住院患者,分为冠状动脉造影阳性(管腔狭窄≥50%)和阴性(管腔狭窄＜50%)2组,对比其心肌缺血的门控心肌灌注显像特点,并进行两样本t检验.结果 冠状动脉造影阳性组19例,其中9例表现为可逆性心肌缺血,10例表现为不可逆性心肌缺血;8例射血分数(EF)升高,为(69.1±2.8)%,11例下降,为(42.8±2.1)%.冠状动脉造影阴性组50例,其中37例表现为可逆性心肌缺血,13例表现为不可逆性心肌缺血;38例EF值升高,为(70.8±4.0)%,12例下降,为(48.9±2.7)%.2组缺血范围[(29.7±17.8)%与(24.1±16.0)%]、缺血严重程度和EF值组间差异均有统计学意义(t=9.28,16.51和2.65,P＜0.001,＜0.001和＜0.01).结论 门控心肌灌注显像发现肥厚型心肌病合并冠心病患者心肌缺血情况要严重于无合并冠心病患者;冠心病对于改变肥厚型心肌病的病理生理过程、自然病程和预后可能起重要作用.%Objective To evaluate the value of gated ~(99)Tc~m-methoxyisobutylisonitrile (MIBI) myocardial perfusion imaging in detection of myocardial ischemia in hypertrophic cardiomyopathy.Methods Sixty-nine patients with clinically proven hypertrophic cardiomyopathy were divided into 2 groups using coronary angiogram as "gold standard":positive group(n=19,narrowing≥50%) and negative group (n=50,narrowing＜50%).Gated ~(99)Tc~m-MIBI myocardial perfusion imaging was performed and positive in all 69 patients (41 males,28 females,aged 35-75 years).Comparative analysis between the two groups was carried out using t-test.Results In the positive group,reversible and irreversible perfusion defects were detected in 9 and 10 patients,respectively.Left ventricular ejection fraction (LVEF) increased to (69.1±2.8)% in 8 patients and decreased to(42.8±2.1)% in 11 patients.In the negative group,reversible and irreversible perfusion defects were found in 37 and 13 patients,respectively.LVEF increased to(70.8±4.0)% in 38 patients and decreased to(48.9±2.7)% in 12 patients.The values of ischemic area,severity and extent of perfusion defect,and LVEF were significantly different between the two groups(t=9.28,16.51,2.65;P＜0.001,＜0.001,＜0.01,respectively).Conclusions Gated ~(99)Tc~m-MIBI myocardial perfusion imaging is valuable in assessing patients with hypertrophic cardiomyopathy.Detection for the presence or absence of coexisting coronary artery disease and myocardial ischemia has an important prognostic indication and management indication for these patients.

摘要： Objective To evaluate the use of gated SPECT in patients with hypertrophic obstructive cardiomyopathy (HOCM) and the effects of percutaneous transluminal septal myocardial ablation (PTSMA) on myocardial perfusion.Methods 99 Tcm-methoxyisobutylisonitrile (MIBI) and 18F-fluorodeoxyglucose (FDG) images were performed in 31 HOCM patients before PFSMA and in 15 patients 3-7 d after PTSMA.The images in different left ventricular segments were analysed by using scores.Results In 99Tcm-MIBI images, uptake decreased at the septal regions in 12 HOCM patients (80.0%, 12/15) after PTSMA, 18F-FDG images also showed decreased uptake at the septal regions in 5 HOCM patients (33.3%, 5/15) after PTSMA.Conclusion 99Tcm-MIBI images might be an important method to evaluate PTSMA results, and 18 F-FDG images showed important value as reference.%目的 了解肥厚梗阻型心肌病(HOCM)患者行经皮室间隔心肌化学消融术(PTSMA)前后心肌灌注和代谢的变化.方法 对31例HOCM患者在PTSMA前进行了99Tcm-甲氧基异丁基异腈(MIBI)灌注显像和18F-脱氧葡萄糖(FDG)代谢显像,其中15例进行术后急性期(3～7d)99Tcm-MIBI灌注显像和18F-FDG代谢显像复查,以半定量记分法评价各室壁节段灌注和代谢变化情况.结果 99Tcm-MIBI灌注显像:90.3%(28/31)的HOCM患者PTSMA术前室间隔放射性浓聚,PTSMA术后80.0%(12/15)的HOCM患者室间隔灌注有不同程度的减低;18F-FDG代谢显像在PTSMA术前54.8%(17/31)的患者表现为代谢异常,术后33.3%(5/15)的患者代谢异常降低,以间隔后段最为明显.结论 99Tcm-MIBI SPECT灌注显像可作为评价PTSMA术后效果的重要手段.18F-FDG代谢显像有重要的参考价值.

摘要： 目的:分析大鼠心肌肥厚过程中microRNAs(miRNAs)的表达变化.方法:通过肾上腹主动脉缩窄(abdominal aortic constriction,AAC)的方法建立大鼠心肌肥厚模型.实时定量PCR检测大鼠肥厚心肌中miRNAs的表达变化.结果:大鼠AAC后1周,心重/体重比以及心肌肥厚标志分子心房钠尿肽、β-重链肌球蛋白的编码基因Nppa、myh7表达明显升高,表明心肌肥厚模型建立成功;对肥厚心肌的miRNAs表达检测表明,miR-199a表达显著升高,miR-1、miR-133、miR-181a及miR-499表达显著降低.AAC 后4周,miR-21、miR-24和miR-214表达显著升高,miR-181a表达显著降低, miR-23a、miR-133、miR-145、miR-199a和miR-499表达无明显改变.结论:心肌肥厚后miRNAs表达发生改变,可能在心肌肥厚病理过程中发挥着重要的调节作用.

摘要： 目的 探讨肥厚型心肌病(HCM)患者心肌99Tcm-甲氧基异丁基异腈(MIBI)早、晚期清除率的变化以及早、晚期清除率与左室壁心肌肥厚程度的关系.方法 对临床确诊为HCM的15例患者行99Tcm-MIBI静态平面及门控SPECT显像.比较HCM患者99Tcm-MIBI早期(注药后90 min)及晚期(注药后4 h)清除率与健康对照组(健康志愿者12名)间的差异(采用SPSS 13.0软件,行t检验),并对早、晚期清除率与左室壁心肌肥厚程度行Pearson直线相关性分析.结果 HCM患者组早期及晚期心肌99Tcm-MIBI清除率分别为(27.77±2.60)%及(42.66±3.30)%,健康对照组分别为(18.90±3.70)%及(31.27±4.04)%,2组比较差异均有统计学意义(t值分别为-7.320,-8.069,P均<0.01).HCM患者组左室壁肥厚心肌最大厚度为(26.53±6.57)mm,健康对照组为(15.92±1.29)mm,2组比较差异亦有统计学意义(t值为-6.110,P<0.01).HCM早期及晚期清除率与左室壁肥厚心肌最大厚度间有较好的相关性(r值分别为0.611及0.873,P<0.05和<0.01).结论 HCM患者心肌99Tcm-MIBI早期及晚期清除率明显高于健康对照组,且早、晚期清除率与左室壁心肌肥厚程度均有一定的相关性.%Objective The aims of this study were two. One was to investigate the changes in early and late washout rates of 99Tcm-methoxyisobutylisonitrile (MIBI) in patients with hypertrophic cardiomyopathy (HCM) and the other was to analyze the relationships between early and late washout rates and the hypertrophic wall thickness of left ventricle. Methods Fifteen patients who were clinically diagnosed with HCM underwent 99Tcm-MIBI static planar and gated SPECT imaging. Early (90 min after the intravenous injection) and late (4 hafter the intravenous injection) washout rates of 99gTcm-MIBI between HCM and normal control groups (n=12)were compared. Linear correlation (Pearson) was assessed between early and late washout rates and the hyper-trophic wall thickness of left ventricle treasured by gated SPECT. Results Statistically higher early and late washout rates of 999Tcm-MIBI were observed in HCM than in normal control groups [(27.77±2.60)% vs (18.90±3.70)%, t=-73.20, P<0.01 and (42.66±3.30) vs (31.27±4.04)%, t=-8.069, P<0.01]. Moreover, statistically higher maximum wall thickness over left ventricle was observed in HCM than in normal control groups [(26.53±6.57)mm vs (15.92±1.29) mm, t=-6.110, P<0.01]. Further-more, significantly positive correlation between early and late washout rates and the maximal wall thickness of left ventricle obtained by gated SPECT was demonstrated (r=0.611, P<0.05 and r=0.873, P<0.01). Conclusions Both early and late washout rates of 99Tcm-MIBI and maximum wall thickness over left ventricle were significantly higher in patients with HCM than in control groups. The higher the maximum wall thickness over left ventricle, the higher early and late washout rates in 99Tcm-MIBI studies was noted.

摘要： 本发明属中药制药领域，涉及中药玄参在制备防治心肌肥大、肥厚性心肌病和慢性心力衰竭药物中的用途。本发明采用国内外学术界公认的多种小鼠及大鼠心肌肥大、心室重构模型对中药玄参的作用进行研究。实验结果揭示，玄参水或醇提物具有明显的抗多种原因所致心肌肥大、心室重构、慢性心衰的作用，其作用机制与抑制肾素—血管紧张素—醛固酮等神经内分泌系统的过度激活明显相关，同时也与降低血压、减慢心率、改善血流动力学的作用相关。玄参可用于制备防治心肌肥大、肥厚性心肌病、慢性心衰的药物，并可减少心肌肥大、肥厚性心肌病和慢性心力衰竭患者心律失常、猝死的发生率。

摘要： 本发明属中药制药领域，涉及中药玄参在制备防治心肌肥大、肥厚性心肌病和慢性心力衰竭药物中的用途。本发明采用国内外学术界公认的多种小鼠及大鼠心肌肥大、心室重构模型对中药玄参的作用进行研究。实验结果揭示，玄参水或醇提物具有明显的抗多种原因所致心肌肥大、心室重构、慢性心衰的作用，其作用机制与抑制肾素—血管紧张素—醛固酮等神经内分泌系统的过度激活明显相关，同时也与降低血压、减慢心率、改善血流动力学的作用相关。玄参可用于制备防治心肌肥大、肥厚性心肌病、慢性心衰的药物，并可减少心肌肥大、肥厚性心肌病和慢性心力衰竭患者心律失常、猝死的发生率。

摘要： 本发明公开了肥厚型心肌病相关的标志分子及其在诊断肥厚型心肌病中的应用，所述肥厚型心肌病相关的标志分子为基因COMP和SERPINE1两者联合，经验证发现，所述标志分子用于诊断肥厚型心肌病时表现出较高的准确性、敏感性和特异性，采用本发明公开的方法进行肥厚型心肌病的诊断，具有准确、简便、快速和经济等特点，本发明为肥厚型心肌病的临床早期分子诊断和预防提供了一种全新的方法。

摘要： 本发明涉及RNA在治疗扩张性心肌病、心肌纤维化及心肌凋亡中的应用，属于生物医药技术领域。本发明提供一种RNA在制备治疗扩张性心肌病药物中的应用以及在制备治疗心肌纤维化及心肌凋亡药物中的应用，RNA的序列为SEQ ID No.1，RNA链中的尿嘧啶U以pseudo U替代。通过本发明，为心肌纤维化，心肌凋亡和扩张性心肌病提供了一种有效的治疗手段，为延缓相关心脏疾病的发生发展以及治疗提供了一种新的路径。

摘要： 本发明涉及一种miRNA在检测心肌肥厚及梗阻型肥厚性心肌病中的应用。所述的miRNA为hsa‑miR‑15a‑5p/hsa‑miR‑16‑5p，所述的检测心肌肥厚为：区分健康人与心肌肥厚患者；所述的检测梗阻型肥厚性心肌病为：检测心肌肥厚的患者是否并发流出道梗阻。

摘要： 本发明涉及心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂。本发明者们发现：具有特定的氨基酸序列的HMGB1片段肽在扩张型心肌病的动物模型中显示心功能的改善、心肌细胞肥大的抑制、心肌纤维化的抑制、以及血管生成促进的效果，在由陈旧性心肌梗塞引起的缺血性心肌病的动物模型中，该特定的HMGB1片段肽也显示心功能的改善、心扩大的抑制、心肌细胞肥大的抑制、心肌纤维化的抑制、以及血管生成促进的效果，以及在高血压性心肌病的动物模型中，该特定的HMGB1片段肽显示心肌细胞肥大的抑制及心肌纤维化的抑制效果。基于这些认知，本发明提供一种含有具有特定的氨基酸序列的HMGB1片段肽的、用于预防和/或治疗心肌病及陈旧性心肌梗塞以及由它们引起的慢性心力衰竭的药物组合物。

摘要： 本发明属于生物医学研究与应用领域，具体涉及人类多能干细胞-遗传性心肌病心肌细胞及其制备技术。本发明提供了一种人类遗传性心肌病-多能干细胞，利用TALEN或CRISPR/CAS9基因组编辑技术，构建人类遗传性心肌病多能干细胞。本发明制得的人类遗传性心肌病变心肌细胞，可以与任意支架材料结合培养形成的各类体外人类遗传性心肌病疾病心肌组织。本发明的人类遗传性心肌病的疾病心肌细胞具备与人类遗传性心肌病患者心肌细胞相似的疾病表型及电生理改变，来源广泛，且能长期体外培养。为寻求有效、新型的治疗手段和筛选有效的相应治疗药物提供了良好的工具和平台。

摘要： 本发明涉及一种与肥厚型心肌病中心肌肥厚程度相关的单核苷酸多态性，以及在肥厚型心肌病严重程度诊断方面的用途。

摘要： 本发明涉及一种扩张性+肥厚性心肌病易感基因的检测方法及芯片，本发明基于目标区域捕获高通量测序技术，通过选取一组与DCM/HCM心血管疾病相关的特异有效基因集合使用自开发探针建库捕获流程及分析软件进行高通量捕获测序分析，旨在通过基因手段找出遗传水平心血管疾病相关基因尤其是DCM/HCM等基因的变异情况以实现易感基因的筛查，对所筛查结果参考美国医学遗传学会(ACMG)和分子病理学会(AMP)指南解读变异。该发明试剂盒与常规高通量测序相比具有针对性强、成本低流程快等优势。

摘要： 本发明公开了一种肥厚性梗阻性心肌病HOCM心脏模型的建立方法及系统。其中，该方法至少包括：采集心脏图像数据；对所述心脏图像数据进行三维重建，得到三维模型；对所述三维模型进行3D打印，得到HOCM心脏模型，可以使用工具测量分析和判断心肌肥厚的范围，以及观察室间隔的增厚情况及其和二尖瓣装置、传导束的关系，从而使医师可以更加清晰直观地观察心室内部肥厚心肌情况，以及与瓣膜系统、传导束的相互关系，得到传统影像学技术所无法提供的直观心脏模型。